Navigation Links
Pharmos Announces Agreement to Sell Certain CB2 Selective Agonists

ISELIN, N.J., Feb. 18 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) announced today that it has entered into an agreement with an Israel based company, Reperio Pharmaceuticals Ltd. (Reperio) for the sale of the patent rights and technical know how related to the compound known as PRS-639,058 and some follow on molecules. These CB2-selective cannabinoids are synthetic compounds which belong to the class of nonclassical cannabinoids and thus display fewer of the undesired psychotropic and cardiovascular side-effects seen with some natural cannabinoids.

Pharmos had developed these compounds in preclinical testing for neuropathic pain. The particular patents and know how subject to this agreement share some of the pharmacological properties with cannabinoids and have a common wide range of beneficial therapeutic indications. In particular, the compounds sold are useful as analgesic, neuroprotective, immunomodulatory and anti-inflammatory agents.

The two companies have executed an Asset Purchase Agreement, which is targeted to close on or before June 6, 2009. As well as customary closing conditions, Reperio must reach consent with the Office of the Chief Scientist to clearly define the assumption of potential liabilities for grant payments that were made to Pharmos during the development of the CB2 program.

The sale is consistent with Pharmos' objectives to conserve its cash resources for the development of Dextofisopam, currently enrolling in a Phase 2b US trial. The Company previously announced the closure of its operations in Israel, effective October 31, 2008.

Two of the Company's former scientists will join Reperio and the arrangement allows for further development of these CB2 assets. As part of the agreement Pharmos will be granted an equity ownership in Reperio and will be entitled to license and royalty fees commensurate with the preclinical development stage of the assets.

About Pharmos Corporation

Pharmos discovers and develops novel therapeutics to treat a range of indications including specific diseases of the nervous system such as disorders of the brain-gut axis (IBS), pain/inflammation, and autoimmune disorders. The Company's lead product in development, dextofisopam, is undergoing Phase 2b testing in IBS patients. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders. These are available for licensing / partnering. Certain of the CB2 assets, as identified, are the subject of the agreement announced in this press release.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmos Corporation Announces That it Will Cease Operations in Israel
2. Pharmos Corporation Reports 2008 Second Quarter Results
3. Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Pharmos Corporation Reports 2008 First Quarter Results
5. Pharmos Corporation Completes Initial Closing of Private Placement
6. Pharmos Corporation Announces Board and Management Changes
7. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
8. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
9. Pharmos Corporation Reports 2007 Third Quarter Results
10. Pharmos Issues Letter to Shareholders
11. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers
Post Your Comments:
(Date:11/24/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that ... and invited investors to participate via webcast. ... 1, 2015 at 11.00 a.m. Eastern Time --> ... 1, 2015 at 11.00 a.m. Eastern Time --> ... NY      Tuesday, December 1, 2015 at 11.00 ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... on behalf of the Toronto Stock Exchange, confirms that ... are no corporate developments that would cause the recent ... --> --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... Chief Financial Officer, will participate in the Piper Jaffray 27 th ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. EST ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... are paramount. Insertion points for in-line sensors can represent a weak spot where ... InTrac 781/784 series of retractable sensor housings , which are designed to tolerate ...
Breaking Biology Technology:
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
Breaking Biology News(10 mins):